The degree of DNA instability as determined by immunohistochemical staining with anti-single-stranded DNA antibody after acid hydrolysis (the DNA instability test) was used as a marker of malignancy. The test was applied to tissues of oral leukoplakia assessed histopathologically as hyperplasia (38 cases), mild (12 cases), moderate (11 cases) and severe (8 cases) dysplasia, and invasive squamous cell carcinoma (SCC, 20 cases). Tissues were subjected to immunohistochemical staining for proliferating cell nuclear antigen (PCNA), p53, DNA-fragmentation factor 45 (DFF45), analysis of various AgNORs parameters, and triple immunostaining for vascular endothelial growth factor (VEGF), CD34, and PCNA. The DNA instability test was positive in 20 (100%) SCC cases, 8 (100%) severe dysplasia cases, 8 (72.7%) moderate dysplasia cases, 6 (50.0%) mild dysplasia cases, and 9 (23.7%) hyperplasia cases, indicating malignancy. The proportion of lesions positive for PCNA, p53, DFF45, and values of AgNORs parameters steadily increased from hyperplasia to mild, moderate and severe dysplasia, and SCC, especially in those showing positive DNA instability test, indicative of malignancy. Based on these results, 44.9% of leukoplakia were malignant tissues, namely carcinoma in situ. The proportion of PCNA-positive vascular endothelial cells in the vicinity of VEGF-positive epithelial lesion was significantly higher than that of negative DNA instability lesions, as revealed by immunohistochemical triple staining for VEGF, CD34, and PCNA. Our results suggest that increased DNA instability, enhanced proliferative activity, p53 mutation, and induction of DFF45 and VEGF may allow cancer cell proliferation, enhance their survival by escaping apoptosis, and provide abundant nutrients during early-stage carcinogenesis of oral leukoplakia.

INTRODUCTION

Oral leukoplakia is regarded as a precancerous or potentially malignant lesion (Kramer et al., 1978), and is defined as “a predominantly white lesion of the oral mucosa that cannot be characterized as any other definable lesion” (Axell et al., 1996). Histopathological grade of dysplasia is the most important indicator of the malignant potential of leukoplakia (Burkhardt, 1985). Dysplasia is characterised by 12 types of general disturbances in the epithelium (Kramer et al., 1978). The diagnosis of epithelial dysplasia, however, requires a considerable experience (Pindborg et al., 1985), and interobserver agreement rates are generally poor, rang-
ing between 49% and 69% (Karabulut et al., 1995).
Several groups have used the 12-histopathological
diagnostic criteria of WHO to diagnose mild dys-
plasia as the presence of two of these features,
moderate dysplasia by 2 to 4 features, and severe
dysplasia by the presence of ≥5 diagnostic features
(Ramaesh et al., 1998). However, others have used
conventional histopathological characterisation as
dysplasia of mild (abnormality less than one-third
of epithelial thickness), moderate (approximately
two-thirds involvement), and severe (full-thickness
abnormality) (Bouquot and Gneppt, 1991; Tsu-
suzuki et al., 1994; Thomson et al., 1999).
The frequency of oral carcinoma in patients with
oral leukoplakia ranges from 2.4% to 70.3% during
a 6-20 year observation period (Einhorn and Wer-
säll., 1967; Silverman et al., 1984; Hansen et al.,
1985; Silverman and Gorsky, 1997; Schepman et al.,
1998; Lee et al., 2000). Furthermore, Lee et al.
(2000) reported that the cancer risk of oral leuko-
plakia with moderate to severe dysplasia was 2.3
times higher than that with hyperplasia or mild dys-
plasia. However, malignancy could also develop in
non-dysplastic lesions such as hyperplasia (Silver-
man et al., 1984; Hansen, et al., 1985; Schepman et
al., 1998; Murti et al., 1998).
As described above, the morphological criteria
used for the diagnosis of malignancy are quite
ambiguous and controversial, making the diagnosis
of oral leukoplakia in clinical specimens often diffi-
cult. In order to enhance accurate diagnosis, many
histochemical and biochemical methods have been
applied to the dysplastic lesions in search for reliable
markers of malignancy. For example, cytokeratin
(Vaidya et al., 1998; Ibrahim et al., 1998), argy-
rophilic nucleolar organiser region staining
(AgNORs) (Wanakulasuriya and Johnson, 1993;
Chattopadhyay et al., 1994; Kobayashi et al., 1995),
proliferating cell nuclear antigen (PCNA) (Tsuij et
al., 1992; Nishioka et al., 1993; Kobayashi et al.,
1995), p53 (Nishioka et al., 1993; Girod et al., 1994;
Tsuij et al., 1995; Murti et al., 1998; Ries et al.,
1998), Bcl-2 (Ravi et al., 1996), Fas (Muraki et al.,
1997), integrin (Gazino et al., 1998; Hakkenen et
al., 1999), vascular endothelial growth factor
(VEGF) (Denhart et al., 1997; Maeda et al., 1998),
cell and nuclear diameters (Ramaesh et al., 1998),
and kinetic parameters of cell proliferation (Thom-
son et al., 1999) have been used for this purpose.
Recently, Lee et al. (2000) demonstrated that a com-
bined biomarker score of chromosomal polysomy,
p53 positivity and loss of heterozygosity was the
strongest predictor for cancer development in oral
leukoplakia.

The above diagnostic tools demonstrate the pres-
ence of abnormal gene expression and protein
synthesis, disturbed cytodifferentiation, stimulat-
ed cell proliferation activity, and DNA abnormali-
ties during the course of progression of overt
malignancy in oral leukoplakia. However, these
could not be used as specific markers for the diag-
nosis of malignancy. In this regard, Fukuda et al.
(1986, 1993) found that nuclear DNA of cancer-
ous cells was less stable than that of comparable
benign tumour cells and normal cells, irrespective
of epithelial or mesenchymal origin. They also
developed the method of differential staining or
immunohistochemical staining of cancerous
cells after denaturation of nuclear DNA by acid
hydrolysis. By using this method (the DNA insta-
bility test), cancerous clones could be identified
during early stages of carcinogenesis in so-called
borderline or precancerous lesions such as col-
orectal adenoma (Nitta et al., 1993), gastric ade-
noma (Otaki et al., 1994), otorhinolaryngeal bor-
derline lesions (Tsuzuki et al., 1994), bone giant
cell tumours (Azuchi et al., 1998), and uterine cer-
vical dysplasia (Khaled et al., 2000).

In the present study, we used the DNA instabili-
ty test as a marker of malignancy to identify can-
cer clones in early-stage leukoplakia. Cancer
clones were recognised by increased DNA insta-
bility in hyperplastic and dysplastic leukoplakia
and exhibited significantly higher values of PCNA
labelling, abnormal AgNORs parameters, and
immunoreactivity for p53, DNA fragmentation
factor 45 (DFF45), and VEGF, compared with
negative lesions.

MATERIALS AND METHODS

Immunohistochemical staining with polyclonal
anti-single-stranded DNA antibody to demon-
strate DNA-instability (DNA-instability test)

(a) Tissue samples
Paraffin-embedded sections (4 μm thick) were
preparated from biopsies or surgically resected
specimens of human oral normal mucosa (7 cas-

334
es), non-dysplastic hyperplasia (38 cases), dysplasia (31 cases), and squamous cell carcinoma (20 cases), after fixation with 10% buffered formalin for 24 hr at room temperature. Clinical diagnosis of leukoplakia was made according to WHO criteria (Kramer et al., 1978). Histopathological classification of dysplasia was performed using conventional criteria described above; mild dysplasia (12 cases), moderate dysplasia (11 cases), and severe dysplasia (8 cases). Tissue sections were deparaffinized with xylene and replaced by ethanol.

(b) Preblocking
After washing in water, intrinsic peroxidase was blocked with 0.3% H₂O₂ solution dissolved in absolute methanol at 20°C for 15 min and rinsed with PBS (pH 7.4). Sections were mounted with 2% skim-milk (Yukijirushi, Sapporo, Japan) dissolved in PBS (pH 7.4) at 37°C for 20 min to block the background adsorption of antiserum. Tissue sections were reacted with the blocking solution [Histofine PO(R), Nichirei, Tokyo, Japan].

(c) Immunohistochemical staining of single-stranded DNA
In the next step, sections were washed in water, and treated with 2N HCl at 30°C for 20 min for acid hydrolysis followed by re-washing in water. They were reacted with a polyclonal antibody to cytidine (Biogenesis, UK, 1:1,500 dilution) at 4°C overnight and rinsed with PBS at (pH 7.4). Sections were reacted with biotinylated goat anti-rabbit IgG [Histofine PO(R), Nichirei] at 37°C for 40 min and rinsed with PBS (pH 7.4), followed by reaction with the avidin-biotin peroxidase complex (Histofine, Nichirei) at 37°C for 30 min, and further rinsed with PBS (pH 7.4).

(d) Co-DAB reaction
In order to visualize the peroxidase colour reaction, sections were incubated with DAB (3,3'-diaminobenzidine tetrahydrochloride) cobalt solution [DAB, Dojin, Kumamoto, Japan, 5 mg dissolved in 100 ml of 0.05 M Tris-HCl buffer (pH 7.4), mixed with 2 ml of 1% CoCl₂ and 10 μl of 30% H₂O₂ solution] at 20°C for 10 min and washed in water. Nuclear counterstaining was performed with Kernechtrot (Kernechtrot, Chroma, Stuttgart, Germany, 100 mg and aluminium sulphate 5 g dissolved in 100 ml distilled water).

(e) Evaluation of DNA-instability test
Sections containing positively stained cells were regarded as positive for malignancy.

Immunohistochemical staining of PCNA, p53 and DNA-fragmentation factor
Serial 4 μm sections were prepared from the same specimens used for the DNA instability test as described above. They were irradiated in a poly-propylene slide holder with a cap filled with 10 mM Na-citrate buffer (pH 6.0), over a period of 10 min, using an autoclave (Hirayama, 1.5 kW, Tokyo). After washing with water, intrinsic peroxidase activity was blocked with 0.3% H₂O₂ solution dissolved in absolute methanol at 20°C for 15 min and rinsed with PBS (pH 7.4). Sections were then mounted with 2% skim-milk (Yukijirushi) dissolved in PBS (pH 7.4) at 37°C for 30 min to block the background adsorption of antiserum, then further reacted with the blocking solution [Histofine PO(M), Nichirei] at 20°C for 5 min. This was followed by reactions with the following primary antibodies at 4°C overnight: monoclonal anti-PCNA antiserum [PC-10, NC-012, Novocastra, Newcastle, UK, 50 μl dissolved in 2.5 ml PBS (pH 7.4), mixed with 0.02% Triton X-100], or monoclonal anti-p53 antibody (Ab-6,Calbiochem, USA, 1:40 dilution). Sections were then washed with PBS (pH 7.4), further reacted with biotinylated rabbit anti-mouse IgG [Histofine PO(M), Nichirei] at 37°C for 30 min, followed by rinsing with PBS (pH 7.4). They were allowed to react with the avidin-biotin peroxidase complex at 37°C for 30 min, and rinsed with PBS (pH 7.4). In order to visualize the peroxidase colour reaction, the sections were incubated with DAB cobalt solution at 20°C for 10 min and washed in water. Nuclear counterstaining was carried out with Kernechtrot. Immunohistochemical staining for DNA-fragmentation factor was performed in a similar fashion except for using polyclonal anti-DNA-fragmentation factor antibody (NCL-DFFp, Novocastra, Newcastle, UK, 1:200 dilution) as the primary antiserum. Biotinylated goat anti-rabbit IgG was selected as the secondary antiserum with the blocking solution for rabbit [Histofine PO(R), Nichirei]. The extent of PCNA-positive staining was evaluated semi-quantitatively by determining the number of positively stained nuclei in at least 500 epithelial cells in all layers per specimen using an
Olympus microscope (×40 objective and ×10 eye piece). As for p53 and DNA-fragmentation factor staining, cases with >5% positively stained cells (counted using the same method described above for PCNA-positive cases) were considered positive.

**Immunohistochemical triple staining for VEGF, CD34 and PCNA**

Specimens obtained from the same tissues used for the other immunohistochemical staining methods were used. Deparaffinized and alcohol-replaced specimens were washed with distilled water. To activate various antigens, sections were irradiated in a manner similar to that described above except for using microwaving (500 W, ER-245, Toshiba, Tokyo), three times, each for 5 min, instead of autoclaving. Immunohistochemical staining for PCNA was carried out first using the method described above, except for omitting the process of skim-milk treatment. After washing with water, sections were reacted with monoclonal anti-endothelial cell marker (CD34) antibody (NCL-END, Novocastra, 1:25 dilution with PBS, pH 7.4) at 4°C overnight. They were then washed with PBS (pH 7.4), and further reacted with biotinylated rabbit anti-mouse IgG [Histofine PO(M), Nichirei] at 37°C for 30 min, followed by rinsing with PBS (pH 7.4). They were allowed to react with the avidin-biotin peroxidase complex (Histofine, Nichirei) at 37°C for 30 min, rinsed with PBS (pH 7.4), and then incubated with DAB solution. Sections were washed with water and reacted overnight with monoclonal anti-VEGF antibody (C-1, Santa Cruz Biotechnology, CA, 1:150 dilution with PBS, pH 7.4) at 4°C. They were washed with PBS (pH 7.4) and further reacted with biotinylated rabbit anti-mouse IgG [Histofine PO(M), Nichirei] at 37°C for 30 min, followed by rinsing with PBS (pH 7.4). Sections were further reacted with biotinylated rabbit antimouse IgG [Histofine SAB-AP(M), Nichirei] at 37°C for 30 min and washed with PBS (pH 7.4), followed by reaction with alkaline phosphatase-labelled streptavidin [Histofine SAB-AP(M), Nichirei] at 37°C for 1 hr and washed with PBS (pH 7.4). In order to visualize the colour reaction of alkaline phosphatase, specimens were dipped in the reaction mixture for 30 min at room temperature. The reaction mixture was prepared by adding 0.1 ml of the substrate solution [10 mg naphthol-AS-BI-phosphate (Sigma, Steinheim, Germany) dissolved in 0.1 ml N,N-dimetyl formamide, Nacalai, Kyoto] to a solution composed of 0.1 ml of 4% fuchsin solution [4.0 g fuchsin basic (Nacalai, Kyoto, Japan) dissolved in 100 ml 2N HCl] and 0.1 ml of 4% sodium nitrite solution [4.0 g sodium nitrite (Nacalai, Kyoto) dissolved in 100 ml distilled water] in 0.2 M Tris HCl buffer (pH 8.2) (Trizma hydrochloride, Sigma, 6.06 g dissolved in 1,000 ml distilled water).

PCNA-positivity was evaluated by determining the number of positively stained nuclei in at least 50 endothelial cells per one stromal area adjacent to VEGF-positive epithelial cell region. As for VEGF, cases with areas of positively stained cells were regarded as positive.

**AgNORs**

Specimens obtained from the same tissues used in other staining procedures were used. Deparaffinized and alcohol replaced specimens were washed with de-ionised and distilled water, and coated with 2 g/dl gelatine dissolved in 1 g/dl formic acid solution mixed with twice the volume of 50 g/dl silver nitrate, and allowed to react at 20°C for 15 min under a safety light (No. LA, Kodak, NY). Specimens were then fixed with Fuji-fix solution (Fujifix, Fuji Photo Film, Tokyo, 445g dissolved in 2.0 l of de-ionised and distilled water) for 1 min at room temperature and thoroughly washed in de-ionised and distilled water. No nuclear counterstaining was performed.

**Quantitative analysis of AgNORs**

The colour image analysis software, MacScope ver 2.56 (Mitani, Fukui, Japan) was used for this analysis. The image of an optical field of a specimen stained by the AgNORs technique was collected with an objective lens (x100) and projected on a cathode ray tube (CRT). The total number of AgNORs in one optical field or in each nucleus was counted manually. The total area (μm²) of all AgNORs per optical field or per nucleus was computed by the software, as well as the mean AgNORs area ±SD per optical field or per nucleus. Three to five optical fields, i.e., roughly about 100 cells, were examined in each specimen. The mean value of the maximum shape irregularity of AgNORs expressed as the degree of deviation from a regular circle, was computed for the most irregularly
shaped AgNORs in 10 nuclei in each specimen, by the same examiner, on a photograph printed from the CRT image with a final magnification of ×1,000.

**Statistical Analysis**

PCNA-index and AgNORs parameters are presented as mean ± standard deviation. Data were analysed using Student’s t-test. Staining for p53, DNA fragmentation factor, VEGF and anti-single-stranded DNA antibody was compared in different lesions by the chi-square test and Fisher’s exact test. A p value <0.05 denoted the presence of a significant statistical difference.

**RESULTS**

The results of immunohistochemical staining of DNA-instability, PCNA, p53, and DFF45 and AgNORs parameters are summarized in Table I. The data for these parameters in relation to the results of the DNA-instability test are also listed in Table II. The PCNA-index of capillary endothelial cells positive for CD34 in the neighbourhood of VEGF-positive and negative epithelial lesions determined by immunohistochemical triple staining are also summarized in Tables I and II.

**DNA-instability test**

After hydrolysis with 2N HCl at 30°C for 20 min, all cancer cells stained positive with anti-single-stranded DNA antibody, indicating increased DNA-instability (positive DNA-instability test, Fig. 1e). On the other hand, normal epithelial cells, stromal fibroblasts, vascular endothelial cells and inflammatory cells in the same slide were negative. In general, almost all cells of dysplastic regions in all cases with severe dysplasia stained positive, indicating that the increased DNA-instability is just comparable to that of cancer cells (Fig. 1d). In 9 (23.7%) cases with hyperplasia without recognizable dysplastic changes, cells in several basal-side layers were diffusely and sporadically stained, with sporadic positively stained cells in the upper layers (Fig. 1a). In 6 (50.0%) cases with mild dysplasia, all cells in dysplastic regions and several upper layer cells without marked dysplasia were diffusely positive, and cells in the top layers and dysplastic areas were also sometimes sporadically stained positively (Fig. 1b). In 8 (72.7%) cases with moderate dysplasia, cells in dysplastic regions occupying basal-side layers forming more than two-thirds of the entire mucosal thickness were diffusely stained, and many sporadically stained cells were noted in the upper layers. In the remaining cases with a negative DNA-instability, no positively stained cells were found. Thus, the extent of immunostaining by anti-single-stranded DNA antibody increased in hyperplastic, dysplastic, and invasive cancer (SCC) lesions. Furthermore, there was a significant difference in staining between these tissues and between different dysplastic lesions (p<0.05), but not between hyperplasia and mild dysplasia.

**PCNA immunohistochemistry**

In normal squamous and hyperplastic squamous epithelium with a negative DNA-instability test, PCNA-labelled cells were well localized in the basal layer showing preserved polarity of cytodifferentiation. The PCNA index was significantly higher in moderate dysplasia, severe dysplasia and in SCC than those in normal and hyperplastic cases (Fig. 1f-j, Table I). Moreover, the PCNA index of DNA-instability-test-positive total dysplastic lesions was significantly higher than that of DNA-instability-test-negative cases (Table II). In all hyperplasia, dysplasia and SCC lesions with positive DNA-instability test, the distribution of PCNA-positive cells coincided well with that of DNA-instability-test-positive cells, with spreading throughout the entire mucosal thickness or more than one-third of the mucosal layer, indicating disturbed cytodifferentiation. In all cancer cases, the distribution of PCNA-positive cells was diffuse and random, indicating marked disturbance of polarity. The PCNA indices of severe dysplasia and SCC were significantly higher than that of mild dysplasia (Table I).

**P53 immunohistochemistry**

Normal squamous epithelia were negative for p53. On the other hand, 6/38 (15.8%) cases of hyperplasia were positive for p53 immunostaining (Fig. 1k). As shown in Table I, the percentages of p53 positive cells in mild, moderate, and severe dysplasia, all dysplastic lesions, and SCC were 33.3, 45.5, 50.0, 41.9 and 65.0, respectively. All these values, with the exception of that of mild dysplasia, were significantly higher than that of...
hyperplasia. There was no difference in the proportion of p53-positive cases with mild, moderate and severe dysplasia; however, the proportion of cases with mild dysplasia was significantly different from that of SCC.

On the other hand, among the 9 DNA-instability test positive hyperplastic lesions, 4 (44.4%) cases were also positive for p53, whereas in the 29 DNA-instability-test-negative cases, only 2 (6.9%) cases expressed p53; the difference between the two types was significant (Table II). In mild dysplasia, the proportions of p53-positive cells in DNA-instability-test-positive and negative cases were 66.7 and 0%, respectively. The proportion of p53-positive cells in moderate dysplasia tended to be higher in DNA-instability-test-positive cases (50.0%) than negative cases (33.3%), albeit statistically insignificant. The proportions of p53-positive cells in the entire group of dysplastic lesions with a positive DNA-instability test (54.6%, including mild, moderate and severe dysplasia) and in the entire group of lesions with leukoplakia (51.6%) were significantly higher than those with a negative DNA-instability test (11.1%, 7.9%). A single case of moderate dysplasia with a negative DNA-instability test was positive for p53, but p53-positive cells were present sparsely and limited to the basal cell layer.

Table I

<table>
<thead>
<tr>
<th></th>
<th>DNA-instability test (%)</th>
<th>PCNA-index of epithelial cells (mean ± S.D.)</th>
<th>p53 (%)</th>
<th>DFF45 (%)</th>
<th>AgNOR (area µm²)</th>
<th>maximum shape irregularity (%)</th>
<th>VEGF (%)</th>
<th>PCNA-index of endothelial cells (mean ± S.D.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>0</td>
<td>11.1 ± 1</td>
<td>0</td>
<td>0</td>
<td>1.79 ± 0.29</td>
<td>1.53 ± 0.34</td>
<td>2.90 ± 0.66</td>
<td>1.90 ± 0.37</td>
</tr>
<tr>
<td>Hyperplasia</td>
<td>23.7 ± 8.6 (n=9)</td>
<td>19.4 ± 6.6</td>
<td>15.8 ± 6.2</td>
<td>23.7 ± 8.6</td>
<td>1.89 ± 0.32</td>
<td>2.03 ± 0.68</td>
<td>3.51 ± 1.25</td>
<td>2.33 ± 0.64</td>
</tr>
<tr>
<td>Mild dysplasia</td>
<td>50.0 ± 13.7 (n=4)</td>
<td>35.3 ± 9.7</td>
<td>33.3 ± 9.7</td>
<td>50.0 ± 13.7</td>
<td>2.53 ± 0.41</td>
<td>2.43 ± 0.74</td>
<td>3.70 ± 2.4</td>
<td>2.53 ± 0.65</td>
</tr>
<tr>
<td>Moderate dysplasia</td>
<td>72.7 ± 13.7 (n=4)</td>
<td>44.3 ± 13.7</td>
<td>45.5 ± 13.7</td>
<td>54.6 ± 13.7</td>
<td>2.86 ± 0.47</td>
<td>2.93 ± 1.34</td>
<td>5.18 ± 2.2</td>
<td>2.56 ± 1.09</td>
</tr>
<tr>
<td>Severe dysplasia</td>
<td>100.0 ± 13.7 (n=4)</td>
<td>63.0 ± 12.9</td>
<td>50.0 ± 12.9</td>
<td>62.5 ± 12.9</td>
<td>3.70 ± 0.50</td>
<td>4.49 ± 1.05</td>
<td>7.52 ± 1.33</td>
<td>3.74 ± 0.42</td>
</tr>
<tr>
<td>Dysplasia total</td>
<td>71.0 ± 13.7 (n=22)</td>
<td>45.6 ± 16.0</td>
<td>41.9 ± 16.0</td>
<td>54.8 ± 16.0</td>
<td>2.95 ± 0.63</td>
<td>3.14 ± 1.33</td>
<td>5.21 ± 2.23</td>
<td>2.86 ± 1.04</td>
</tr>
<tr>
<td>SCC</td>
<td>100.0 ± 13.7 (n=20)</td>
<td>68.8 ± 13.9</td>
<td>65.0 ± 13.9</td>
<td>75.0 ± 13.9</td>
<td>4.28 ± 1.33</td>
<td>4.68 ± 1.09</td>
<td>7.30 ± 2.25</td>
<td>4.29 ± 1.26</td>
</tr>
</tbody>
</table>

(★P<0.05 vs hyperplasia)  
(●P<0.05 vs normal cases)  
(SCC: Squamous Cell Carcinoma)
Table II
Comparison of different biological parameters in DNA-instability test positive and negative cases of leukoplakia. Differences in PCNA index and AgNORs parameters were examined by the Student’s t-test. Differences in p53, DFF45, and VEGF were examined by the chi-square test. Significant differences are indicated by asterisks.

<table>
<thead>
<tr>
<th>DNA instability test</th>
<th>PCNA-index of epithelial cells (mean±S.D.)</th>
<th>p53</th>
<th>DFF45</th>
<th>AgNOR (mean±S.D.)</th>
<th>VEGF</th>
<th>PCNA-index of endothelial cells (mean±S.D.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>number</td>
<td>area</td>
<td>largest size</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(µm²)</td>
<td>(µm²)</td>
<td>(%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperplasia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>positive (n=38)</td>
<td>23.7 ± 6.3</td>
<td>44.4*</td>
<td>(4/9)</td>
<td>6.9 ± 6.6</td>
<td>3.28±1.66</td>
<td>1.73±0.15</td>
</tr>
<tr>
<td>negative (n=29)</td>
<td>76.3 ± 7.6</td>
<td>66.7*</td>
<td>(6/9)</td>
<td>10.3 ± 4.9</td>
<td>2.26±0.60</td>
<td>1.73±0.15</td>
</tr>
<tr>
<td>Mild dysplasia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>positive (n=6)</td>
<td>50.0 ± 6.1</td>
<td>66.7*</td>
<td>(4/6)</td>
<td>33.3 ± 2.6</td>
<td>3.49±1.14</td>
<td>2.73±0.27</td>
</tr>
<tr>
<td>negative (n=6)</td>
<td>50.0 ± 6.6</td>
<td>66.7*</td>
<td>(4/6)</td>
<td>33.3 ± 2.6</td>
<td>3.49±1.14</td>
<td>2.73±0.27</td>
</tr>
<tr>
<td>Moderate dysplasia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>positive (n=11)</td>
<td>72.7 ± 11.8*</td>
<td>62.5*</td>
<td>(5/8)</td>
<td>33.3 ± 1.5</td>
<td>2.19±1.08</td>
<td>2.45±0.28</td>
</tr>
<tr>
<td>negative (n=3)</td>
<td>27.3 ± 29.5</td>
<td>33.3</td>
<td>(1/3)</td>
<td>33.3 ± 1.5</td>
<td>2.19±1.08</td>
<td>2.45±0.28</td>
</tr>
<tr>
<td>Severe dysplasia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>all-positive (n=8)</td>
<td>100.0 ± 12.9</td>
<td>62.5</td>
<td>(4/8)</td>
<td>3.70±0.5</td>
<td>4.49±1.05</td>
<td>7.52±1.33</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysplasia total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>positive (n=22)</td>
<td>71.0 ± 13.7*</td>
<td>54.6</td>
<td>(12/22)</td>
<td>3.19±0.5</td>
<td>5.86±2.28</td>
<td>3.51±1.33</td>
</tr>
<tr>
<td>negative (n=9)</td>
<td>29.0 ± 29.8</td>
<td>63.6</td>
<td>(11/19)</td>
<td>33.3 ± 3.9</td>
<td>2.36±0.25</td>
<td>2.75±0.78</td>
</tr>
<tr>
<td>Leukoplakia total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>positive (n=69)</td>
<td>44.9 ± 17.8*</td>
<td>51.6</td>
<td>(16/31)</td>
<td>2.85±0.74</td>
<td>3.13±1.35</td>
<td>5.31±2.19</td>
</tr>
<tr>
<td>negative (n=38)</td>
<td>55.1 ± 20.6</td>
<td>64.5</td>
<td>(20/31)</td>
<td>3.43±1.18</td>
<td>2.32±0.64</td>
<td>7.9 (3/38)</td>
</tr>
</tbody>
</table>

(*: P<0.05, vs DNA instability test negative cases)
Fig. 1 - Immunohistochemical staining and AgNOR staining. Hyperplasia (a, f, k, p, u), mild dysplasia (b, g, l, q, v), moderate dysplasia (c, h, m, r, w), severe dysplasia (d, i, n, s, x), and squamous cell carcinoma (e, j, o, t, y). DNA instability test (a-e), PCNA (f-j), p53 (k-o), DFF45 (p-t), magnification, ×100. AgNORs (u-y), magnification, ×800.
In comparison, few p53-positive cells were present in the basal layer in hyperplasia and mild dysplasia, in more than one-third of the basal layer in moderate dysplasia, and in almost the entire thickness of the mucosa in severe dysplasia (Fig. 1 k,l,m,n). In invasive cancer lesions, almost all cancer cells were p53-positive (Fig. 1o).

**DNA-fragmentation factor 45 immunohistochemistry**

Normal squamous epithelium was negative for DFF45. The proportions of DFF45-positive cases among hyperplasia, mild, moderate and severe dysplasia, total dysplastic lesions and SCC were 23.7, 50.0, 54.6, 62.5, 54.8, and 75%, respectively. The proportions of DFF45-positive cases with moderate and severe dysplasia, total dysplastic lesions and SCC were significantly different from that of hyperplasia, but those with each form of dysplasia were not different (Table I).

As shown in Table II, the proportion of DFF45-positive cases with a positive DNA-instability test was significantly higher than those with a negative test. The distribution of DFF45-positive cells in all cases correlated well with that of DNA-instability test positive cells (Fig. 1 p,q,r,s,t).

**AgNORs parameters**

AgNORs parameters were significantly higher in dysplasia and SCC lesions than in normal squamous epithelium (Table I). In hyperplasia, the largest size parameter of AgNORs was significantly different from that of normal squamous epithelium. The maximum shape-irregularity parameter of dysplastic and SCC lesions was significantly higher than that of normal squamous epithelium, and the values of severe dysplasia and SCC were significantly higher than that of hyperplasia. AgNORs parameters of hyperplasia, mild, moderate and severe dysplasias, and total dysplastic lesions with a positive DNA-instability test were significantly higher than those of cases with a negative DNA-instability test.

**Triple immunostaining for VEGF, CD34 and PCNA**

VEGF-positive lesions contained many pale red cells stained with diffuse staining of the cytoplasm. CD34 staining appeared as a thin brownish staining of the cytoplasm of vascular endothelial cells. Both epithelial cells and vascular endothelial cells in the proliferative phases stained brown-black in tissues immunostained for PCNA (Fig. 2a,b, c, d).

**DISCUSSION**

The DNA-instability-test has been proposed by us as a specific marker of malignancy, irrespective of the epithelial or mesenchymal origin of tumors (Fukuda et al., 1986, 1993; Nitta et al., 1993; Ota-ki et al., 1994; Tsuzuki et al., 1994; Azuchi et al., 1998; Khaled et al., 2000). The method of differentially staining malignant cells either with acridine orange or anti-single-stranded DNA is based on the abundant production of denatured single-stranded DNA in cancerous cells after acid hydrolysis. Since the first report (Fukuda et al., 1986), we have applied the DNA-instability test in situ on more than 20,000 human malignancies: in our experience, this proved to be a reliable marker of malignant transformation, which should be applied in parallel with other markers that are already universally accepted.

Based on DNA-instability by acid hydrolysis, about a quarter of our cases of oral hyperplasia showed increased DNA-instability compared with invasive squamous cell carcinoma, suggesting that these lesions could be classified as malignant (Fig. 1a). Furthermore, the proportion of cases with a positive DNA-instability test increased progressively in mild, moderate and severe dysplastic
lesions (50.0, 72.7, and 100%, respectively) (Fig. 1 b,c,d), and all cancer cells of SCC lesions with a positive DNA-instability test were strongly positive (Fig. 1e). Moreover, positive immunostaining for PCNA, p53, DFF45, VEGF, and AgNORs parameters were noted in hyperplasia, and steadily increased along the course of progression from mild, moderate and severe dysplasia to invasive SCC (Tables I and II).

Our results showed that tissues with a positive DNA-instability test often exhibited abnormally high values for these biomarkers. However, they could not be distinguished from cases negative for these biomarkers, including the DNA-instability test, by morphological examination, because the degree of cellular atypia in these tissues was often not markedly pronounced, except for severe dysplasia and SCC.

Based on these findings, we herein propose the concept of “procancer” (as opposed to “pre-cancer”) as being a unique stage during the course of carcinogenesis and cancer progression. We designate the term to cancer clones at the very early stages of malignant progression without distinguishable morphological atypia but with a positive DNA-instability test and positive staining for various biomarkers such as PCNA, p53, DFF45, VEGF and AgNORs parameters. We also define the abnormal positive staining of these biomarkers including the DNA-instability test as “functional atypia”, compared to the ordinary morphological atypia. While morphological criteria seem to be the most reliable markers for the diagnosis of malignancy, it appears that a certain period is required before the degree of morphological atypia is manifested histopathologically to allow the diagnosis of malignancy, even after the formation of cancer clones. Increased DNA-instability as revealed by immunohistochemical staining with anti-single-stranded DNA antiserum after mild acid hydrolysis seems to reflect abundant qualitative alterations of DNA molecules within the cell nucleus. These DNA alterations allow the cell to manifest many abnormal biomarkers, which are suppressed in otherwise normal cells, and give rise to many different sub-populations through repeated mitosis.

PCNA, an auxiliary protein for DNA polymerase delta, plays an important role in the initiation of cell proliferation (Bravo et al., 1987; Jaskulsky et al., 1988). Prescreening of monoclonal anti-PCNA antiserum used in the present study revealed that it reacted with all proliferating cells but not with mature cells and G0 cells. We defined, therefore, the percentage of PCNA-positive cells as the PCNA index, which seems to reflect the relative size of the proliferating cell fraction or growth fraction. Our results showed
that the PCNA index steadily increased along the course of progression of malignancy, in agreement with other studies (Tsuji et al., 1992; Tsuzuki et al., 1994; Kobayashi et al., 1995), especially in tissues with a positive DNA-instability test (Fig. 1f-j, Tables I and II).

Another important finding obtained by PCNA immunohistochemistry used in the present study is the loss of polarity of PCNA-positive cells, particularly in dysplasia and cancer lesions. In normal squamous epithelium, PCNA-positive cells were well localized in the basal layer, but the normal distribution was more or less disturbed in hyperplasia and mild dysplasia, especially in cases with a positive DNA-instability test, and remarkably disturbed in higher grade dysplasia and SCC. This finding indicates the presence of disturbed cell differentiation and proliferation in these lesions, and confirms the malignant characteristics of these tissues.

Wild type p53 protein plays a negative role in regulating cell proliferation by controlling entry of the cell into the S phase and protecting against carcinogenesis (Finlay et al., 1988; Hollstein et al., 1991). Mutated p53 protein can be detected by immunohistochemistry (Bartek et al., 1990). The reported proportions of p53-positive lesions in hyperplastic, dysplastic and SCC cases are 21% (Girod et al., 1994), 36-55% (Kaur et al., 1994; Girod et al., 1994), and 34-78% (Nishioka et al., 1993; Kaur et al., 1994; Girod et al., 1994; Tuji et al., 1995), respectively. In this regard, Girod et al. (1994) demonstrated that the expression of mutant p53 protein intercorrelated with the degree of dysplasia, suggesting that it could be used as a good marker of malignant potential of oral leukoplaikia (Tuji et al., 1995; Lee et al., 2000), although other investigators could not confirm these findings (Murti et al., 1998; Ries et al., 1998). In the present study, the proportion of p53-positive hyperplastic lesions was 15.8%, but increased to 44.4% in hyperplastic lesions with a positive DNA-instability test and a further increase was noted in higher grade dysplasias and SCC. These results indicate that p53 mutation could be regarded as an early event during the sequential stages of oral carcinogenesis, which enhances further progression.

DNA fragmentation factor (DFF) plays an important role in the apoptotic pathway, which is activated by caspase 3, and is involved in the formation of nuclear DNA fragments. DFF is a heterodimeric protein of 40 and 45 kDa which is activated when DFF is cleaved by caspase-3. Of the two enzymatically cleaved fragments of DFF, the 40 kDa fragment (DFF-40) is the active component and is responsible for triggering chromatin condensation (Liu et al., 1997; Enari et al., 1998; Sabol et al., 1998; Samejima and Earnshaw, 1998; Sasaki et al., 1999). Increased proliferative activity, as revealed by PCNA immunohistochemistry and by the abnormal overexpression of apoptosis-related factors such as p53 and DFF45, seems to be an important feature of cancer cells and is associated with favourable survival of these cells. The abnormally high expression of DFF45 may be interpreted as induction of cancer cells to escape the apoptotic process. Induction of DFF45 protein should block the DNase activity of DFF40, thus allowing cancer cells to escape DNA fragmentation immediately before the final step of apoptosis.

Angiogenesis is an important process for tumour growth. Furthermore, VEGF is a specific mitogen for endothelial cells; it is overexpressed in oral high-grade dysplasia and SCC (Denhart et al., 1997) and, in fact, has been previously used as a prognostic factor of oral SCC (Maeda et al., 1998). In the present study, 21.1% of hyperplastic lesions were VEGF-positive. Furthermore, the proportion increased to 44.4% in the same cases with a positive DNA-instability test. Furthermore, VEGF overexpression may be an early event in oral carcinogenesis (Fig. 2, Tables I and II). Furthermore, PCNA indices of vascular endothelial cells in VEGF-positive cases were significantly high as revealed in triple immunostaining for VEGF, CD34, and PCNA (Fig. 2, Tables I and II). Another interesting finding in our study was the progressive increase in the proportion of VEGF-positive cases along the course of cancer progression, especially in cases with a positive DNA-instability test (Table II).

Nucleolar organizer regions (NORs) are chromosomal regions where genes for the major ribosomal RNA (18s, 5-8s, and 28s) are located (Jordan, 1984). Several studies have shown that the size and number of AgNORs reflect the capability of cell proliferation (Reeves et al., 1984; Trene et al., 1991; Carmen et al., 1992) or the degree of malignancy (Arden et al., 1985; Egan and Crocker, 1992), although others have reported contradictory results (Griffiths et al., 1989). In lesions of the oral cavity,
several groups have reported a positive correlation between AgNORs number and the degree of dysplasia and overt malignancy (Sano et al., 1991; Warnakulasuriya and Johnson, 1993; Kobayashi et al., 1995; Chattopadhyay et al., 1994). Tsuizuki et al. (1994) indicated that the AgNORs numbers and the values of maximum shape irregularities of AgNORs were significantly higher in oral dysplasia and SCC than in hyperplasia. In the present study, all AgNORs parameters including the maximum shape–irregularity, were significantly higher in dysplasia and SCC as compared with those of normal squamous epithelium, especially in cases with a positive DNA-instability test; and these values increased with progression to higher grade dysplasia and SCC.

The characteristic features described in “procancer” cells and cancer cells should favour proliferation of the descendants, enhance their survival by escaping the apoptotic process, and promote the availability of nutritional substances. These changes will enable these cells to produce more malignant clones with invasive and metastatic capabilities, although it is also possible that “procancer” cells may disappear by the escalating movement of squamous cells in the mucosa. Taken together, it is important to detect “procancer” clones at the early stages of carcinogenesis using effective biomarkers, and identify “functional atypia” by the DNA instability test in addition to the ordinary diagnostic criteria of morphological atypia, to improve prognosis in patients with oral leukoplakia.

REFERENCES


Griffiths A.P., Butler C.W., Roverts P., Dixon M.F., and Quirke P.: Silver - stained structures (AgNORs), their dependence on tissue fixation and absence of prognostic relevance in rectal adenocarcinoma. J. Pathol. 159, 121-127, 1989.


